Telormedix raises $19 million

Cancer and immune company Telormedix (Lugano-Bioggio, Switzerland) raised CHF21 million ($19 million) in a series A round led by Aravis Venture. Other investors included ProQuest Investments; BSI; Nextech Venture; and Generali Insurance Group. Telormedix's lead compound is TMX-101, a small molecule immunomodulator that is expected to enter Phase I/II testing next year for bladder cancer. ...